8-K: PHIO PHARMACEUTICALS: Stockholders Approve Incentive Plan, Re-elect Directors

Phio Pharmaceuticals Corp. stockholders approved an amendment to the 2020 Long Term Incentive Plan, increasing available shares by 950,000, and re-elected all six directors at the 2025 Annual Meeting.

Summary

• Held the 2025 Annual Meeting of Stockholders on September 11, 2025.
• Stockholders elected all six directors to serve until the 2026 Annual Meeting of Stockholders.
• Ratified Grant Thornton, LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• Approved an amendment and restatement of the 2020 Long Term Incentive Plan, increasing the number of shares of common stock available for issuance by 950,000, to a total of 1,023,017 shares.
• Approved, by non-binding advisory vote, the compensation of named executive officers (Say on Pay).
• Approved, by non-binding advisory vote, 3 years as the preferred frequency for future advisory votes on the compensation of named executive officers (Say on Frequency).
• There were 4,798,154 shares of common stock issued and outstanding at the close of business on July 18, 2025, the record date for eligibility to vote.
• A total of 2,374,235 shares of common stock were present (in person virtually or represented by valid proxy) at the Annual Meeting.

Sentiment

Score: 7

Explanation: The filing indicates stable corporate governance with all directors re-elected and key proposals approved by stockholders. The increase in the incentive plan shares is a positive for employee retention. The only minor concern is the high number of broker non-votes, which suggests a degree of shareholder disengagement on certain matters.

Positives

• Continuity of leadership with the re-election of all six directors.
• Shareholder approval of the amended 2020 Long Term Incentive Plan, which can aid in attracting and retaining key talent.
• Ratification of the independent auditor, Grant Thornton, LLP, ensuring continued financial oversight.
• Shareholder approval of executive compensation (Say on Pay) indicates alignment with management's compensation structure.
• Clear guidance from shareholders on the frequency of future Say on Pay votes (every three years) provides predictability for corporate governance.

Negatives

• A significant number of broker non-votes (1,828,465) for the election of directors, the incentive plan amendment, and Say on Pay, indicating a large portion of shares were not voted on these discretionary matters.
• While approved, 152,069 votes were cast against the amendment to the 2020 Long Term Incentive Plan.

Future Outlook

The Board of Directors has determined to include a stockholder advisory vote on the compensation of named executive officers in its annual meeting proxy materials once every three years, consistent with the advisory vote of stockholders. All elected directors will serve until the 2026 Annual Meeting of Stockholders.

Management Comments

• The Company's Board of Directors has determined, in light of and consistent with the advisory vote of the Company's stockholders as to the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers, to include a stockholder advisory vote on the compensation of the Company's named executive officers in its annual meeting proxy materials once every three years until the next advisory vote on the frequency of stockholder votes on the compensation of the Company's named executive officers.

Industry Context

This filing reflects routine corporate governance activities common across publicly traded companies, including annual director elections, auditor ratification, and adjustments to long-term incentive plans. The approval of an increased share pool for the incentive plan is a standard practice for companies seeking to maintain competitive compensation structures to attract and retain talent in the biotechnology or pharmaceutical sector.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Maintained continuity of the Board of Directors, approved executive compensation, and provided input on governance matters. The dilution from the incentive plan is a consideration, but it is intended for employee motivation and retention.
• **Employees/Executives**: Benefit from an increased pool of shares available for equity compensation under the 2020 Long Term Incentive Plan, enhancing motivation and retention.

Next Steps

• The Company will hold its 2026 Annual Meeting of Stockholders.
• The Company will include a stockholder advisory vote on executive compensation in its annual meeting proxy materials once every three years.

Key Dates

Recommendation

This filing primarily details routine corporate governance matters and the approval of an employee incentive plan. While these are positive for operational stability and employee retention, the filing does not contain sufficient financial or operational performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial disclosures for a comprehensive investment decision.

Keywords

PHIO Pharmaceuticals, SEC Filing, 8-K, Annual Meeting, Stockholder Vote, Long Term Incentive Plan, Executive Compensation, Corporate Governance, Director Election, Auditor Ratification, PHIO